D2d becomes the first NIDDK supported trial to use IRBShare

D2d becomes the first NIDDK supported trial to use IRBShare

Obtaining IRB approval from each separate collaborating clinical site has long been considered a major reason for delaying the start of activities in multi-center trials. D2d becomes the first NIDDK-supported trial and only the fifth NIH-supported study to join the IRB Share program, which allows a clinical site to partner with another IRB for a specific study, thereby avoiding duplication of efforts.

SHARE IT:

Comments are closed.

D2d | Division of Endocrinology, Diabetes and Metabolism | Tufts Medical Center | Boston MA
Copyright © D2d study. All rights reserved.